South Korea’s Ministry of Food and Drug Safety (MFDS) approved Curocell Inc.’s Rimqarto (anbalcabtagene-autoleucel; anbal-cel) for advanced diffuse large B-cell lymphoma, marking the first homegrown CAR T-cell therapy in the country. The approval, dated April 29, expands Curocell’s commercial pathway for an investigational CAR T product that had progressed through clinical development to gain regulatory authorization. For the broader market, the decision signals accelerating domestic manufacturing and development efforts for complex cell therapies in Asia, where reimbursement and access models often determine real-world adoption. The approval also strengthens the competitive landscape for CAR T in South Korea, where follow-on indications and future line expansion will be key to commercial performance.